CV McDowell: Prescriptions That Paid the Marketer

In the CV McDowell settlement, the former owners of the telemarketing business agreed to pay at least $4 million to resolve allegations that they generated compounded-drug prescriptions for pharmacy kickbacks. The government alleged that the business helped choose formulas for their reimbursement, found people to accept them and paid remote prescribers who often never meaningfully examined those people. For someone inside a pharmacy or call center, the revealing question is who chose the medication before the patient ever reached a prescriber.

The Justice Department announced the civil settlement on March 16, 2021. The marketing business operated in Fort Lauderdale under names including CV McDowell and J&J Tel Marketing. Pharmacies billed many of the prescriptions to TRICARE, the federal health care program for active-duty military personnel, military retirees and military dependents. A former employee of a pharmacy receiving the prescriptions brought the whistleblower case.

How the Telemarketing and Prescription Chain Worked

The alleged arrangement paid the marketing businesses half of what TRICARE reimbursed for each prescription they sent to participating compounding pharmacies. That connected the marketer’s income directly to the pharmacy’s government payment.

CV McDowell, LLC and J&J Tel Marketing, LLC were separate Florida companies under the same ownership and control, both engaged in telemarketing compounded prescription drugs. According to the Justice Department, the businesses solicited prospective patients to accept compounded drugs regardless of need. They procured prescriptions and sent them to pharmacies that agreed to the payment arrangement. The owners and marketing businesses also worked with pharmacies to identify formulas that would maximize reimbursement, then sought large volumes of prescriptions for those formulas.

The formula decision matters as much as the referral. In the government’s account, the businesses chose drugs for what the payer would reimburse and then sought prescriptions for them. Under that alleged arrangement, a health care program for military families paid for drugs chosen for their reimbursement, regardless of the patient’s need.

In many cases, the government alleged, the marketing businesses paid telemedicine providers who prescribed expensive compounded drugs without seeing the patients or conducting any meaningful medical examination. The prescription supplied the connection between the sales effort and the pharmacy claim.

That is also why the business relationships matter. In remote care, the company recruiting the patient, the clinician signing the prescription and the business submitting the insurance claim can be different organizations. A pharmacy’s name on the claim did not tell the whole story of how the prescription reached it.

What the Settlement Payment Covered

The announced minimum was not a cap. The civil agreement accompanying the Justice Department’s announcement required additional money if specified property-sale conditions were met. Both companies were parties to that agreement, while the former owners collectively promised payment.

It called for an initial payment of $1 million. Another payment was tied to a former owner’s Fort Lauderdale property, with a $1.7 million floor and a larger payment if the sale’s net proceeds crossed the threshold in the agreement. The U.S. Attorney’s Office subsequently reported that the owners had paid the announced minimum in its January 7, 2022 collections announcement. Pharmacies and other businesses in the same whistleblower case reached separate settlements.

Prescription Sales Described as Marketing Services

In the HealthRight and Vici Marketing case, the government alleged that prescription sales to pharmacies were labeled marketing services. The same operating model appears in the Health and Human Services Office of Inspector General’s July 2022 telemedicine fraud alert. The alert describes companies recruiting patients and practitioners, paying for orders with little patient interaction, and selling the resulting orders to businesses that bill federal programs.

That later alert describes a broader healthcare industry pattern. The CV McDowell allegations show its particular economics: a formula selected for reimbursement, a prescription procured through telemedicine and a pharmacy paying the marketer from the resulting receipts.

What Evidence Is Needed to Prove Fraud?

For an arrangement like this, the useful evidence connects what the patient needed, what the prescriber actually did and how the pharmacy payment reached the marketer. We examine those connections with the insider who knows the business.

A call-center employee may know what patients were offered and how their information moved to a prescriber. A clinician may know what medical information was available before signing. Pharmacy and accounting employees may know which formula was requested, where the prescription originated and how the marketing payment was calculated. Those are different views of the same transaction.

A 2024 Rutgers University Law Review analysis, Plausible Cause: Connecting the FCA and AKS in the Context of Health Care Fraud, examines the problem of connecting a kickback arrangement to the claims it produces. It argues for judging that connection by how the kickback scheme could have produced the bills at issue.

Applied here, that perspective puts the prescription, reimbursement and marketer’s payment together. A marketing agreement may explain the payment formula, while the prescription and payment records show which transactions followed it. An insider’s account of why a formula was selected can explain something the claim alone cannot: whether reimbursement drove the decision before clinical need entered the picture.

How Much of a Settlement Does a Whistleblower Get?

In the CV McDowell case, the former pharmacy employee’s share was handled through a separate agreement with the United States after the announced settlement. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know Why the Prescription Was Sent

If you know how a pharmacy’s receipts became a marketer’s payment, speak with our whistleblower experts. We build the case with you around the prescribing decisions, referral terms and money you can explain, and bring in telehealth fraud whistleblower lawyers who understand prescription kickbacks. We stay beside you through the case, turning your view inside the business into a clear account of how TRICARE was cheated.